In those patients with type 2 diabetes and established ASCVD, or in those with established chronic kidney disease or heart failure, the consensus recommends use of GLP‐1RAs or SGLT2 inhibitors with proven CV benefits.35 This evidence concerns the gene SLC5A2 and chronic kidney disease.